The groups with and without biomarker evidence of AD pathology (i.e. low and high p-tau/Aβ42 ratio) did not show a clear trend in clinical agreement or ICCs, but the high p-tau/Aβ42 group did have wider 95% limits of agreement from Bland-Altman plots for all four sleep parameters in comparing scEEG vs. actigraphy. This evidence concerns the gene MAPT and Alzheimer disease.